Serological response to a third dose of SARS-CoV-2 vaccine according to previous infection history

The IgG antibody titer against SARS-CoV-2 receptor binding protein (RBD) after mRNA vaccine were compared between those with and without previous infection (PI) for up to 48 weeks. Though sustained higher IgG-RBD were observed in the PI group after two doses of vaccines, both groups benefited from t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ota, Kenji, Murakami, Satoshi, Ishihara, Kaori, Sasaki, Daisuke, Usui, Tetsuya, Mitsumoto-Kaseida, Fujiko, Sakamoto, Kei, Kosai, Kosuke, Hasegawa, Hiroo, Takazono, Takahiro, Furumoto, Akitsugu, Asoh, Norichika, Yoshimine, Hiroyuki, Sawai, Toyomitsu, Onizuka, Masanari, Makimoto, Noriaki, Izumikawa, Koichi, Mukae, Hiroshi, Kohno, Shigeru, Yanagihara, Katsunori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Short communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022459/
https://www.ncbi.nlm.nih.gov/pubmed/36960104
http://dx.doi.org/10.1016/j.jvacx.2023.100282
Descripción
Sumario:The IgG antibody titer against SARS-CoV-2 receptor binding protein (RBD) after mRNA vaccine were compared between those with and without previous infection (PI) for up to 48 weeks. Though sustained higher IgG-RBD were observed in the PI group after two doses of vaccines, both groups benefited from the booster shots of the third vaccine. This data supports the necessity of the booster shots to those with PI.

Ejemplares similares